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Abstract
Background:  The tumour suppressor protein p53 is a sequence specific DNA-binding
transcription regulator, which exerts its versatile roles in genome protection and apoptosis by
affecting the expression of a large number of genes. In an attempt to obtain a better understanding
of the mechanisms by which p53 transcription function is regulated, we studied p53 interactions.
Results: We identified BIP2 (Bric-à-brac interacting protein 2), the fly homolog of TAF3, a histone
fold and a plant homeodomain containing subunit of TFIID, as an interacting partner of Drosophila
melanogaster p53 (Dmp53). We detected physical interaction between the C terminus of Dmp53
and the central region of TAF3 both in yeast two hybrid assays and in vitro. Interestingly, DmTAF3
can also interact with human p53, and mammalian TAF3 can bind to both Dmp53 and human p53.
This evolutionarily conserved interaction is functionally significant, since elevated TAF3 expression
severely and selectively inhibits transcription activation by p53 in human cell lines, and it decreases
the level of the p53 protein as well.
Conclusion:  We identified TAF3 as an evolutionarily conserved negative regulator of p53
transcription activation function.
Background
The p53 tumour suppressor protein orchestrates cellular
response to genotoxic stress such as DNA damage, acti-
vated oncogenes and other metabolic changes [1]. In
unstressed cells, p53 is kept at a low level through the
action of various ubiquitin ligases [2], while cellular stress
results in the stabilization of p53 and its activation as a
transcription factor. Although activated p53 is able to
induce cell death via transcription-independent ways [3],
importantly, it influences the transcription of a large
number of genes, that in turn promote cell cycle arrest,
DNA repair or apoptosis [4]. The multiple mechanisms
that stabilize and activate p53 include post-translational
modifications and interactions with different co-factors.
For example, upon DNA damage resulting from ionizing
radiation p53 is phosphorylated by ATM/ATR and Chk1/
Chk2 kinases [5,6]. Activation of p53 upon UV radiation
is less well understood, among other mechanisms, it may
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involve p33ING2 that increases the transcriptional-trans-
activation activity of p53 by enhancing its acetylation [7].
Interestingly, p33ING2 is a plant homeodomain (PHD)
containing protein [7].
In vertebrates, the p53 gene has two other homologs, p63
and p73. Both of them express several isoforms through
alternative promoter usage and alternative splicing,
thereby generating a multitude of p53-related proteins
that participate in the regulation of p53 transcriptional
activity [8,9]. The only Drosophila  homolog of p53,
Dmp53, shares limited conservation with mammalian
p53 at the sequence level, yet the two proteins are similar
in domain structure and their residues critical for DNA
binding are well preserved [10-12]. Importantly, Dmp53
is able to bind to human p53 recognition sites and acti-
vate transcription through these sites. Dmp53 null mutant
flies are viable under normal circumstances, however,
they show genomic instability and sensitivity to ionizing
and UV radiation [13-15]. Overexpression of wild type
p53 or Dmp53 in flies induces cell death, while expres-
sion of dominant negative Dmp53 inhibits apoptosis
induced by genotoxic stimuli [10,12,16]. In response to
DNA damage, Dmp53 induces DNA repair or pro-
grammed cell death by activating the expression of its tar-
get genes [15,17,18]. Activation of Dmp53 apparently
does not involve stabilization of the protein, but similarly
to its human counterpart, Dmp53 is phosphorylated by
Chk2 and this modification is necessary for the induction
of Dmp53 dependent apoptosis [18,19].
Activation domains of various transcription factors are
able to interact directly with TATA binding protein (TBP)
associated factors (TAFs), thus TAFs are thought to serve as
bridging factors between sequence-specific transcription
factors and the basal transcriptional machinery [20]. The
p53 protein has also been found to interact with several
components of the TFIID complex. The N-terminal tran-
scriptional activation domain of p53 binds to TAF1, TAF6
and TAF9 [21,22]. While binding of TAF9 results in stabi-
lization and activation of p53 [23,24], TAF1 phosphor-
ylates p53 and promotes its degradation [25,26]. These
interactions are evolutionarily conserved, since Drosophila
TAFs and TBP can functionally interact with human p53
in heterolog systems [20].
DmTAF3/BIP2 (Bric-à-brac Interacting Protein 2) was first
identified in a yeast two hybrid screen as an interacting
partner of BAB1 and BAB2 (Bric à brac 1 and 2) Drosophila
transcription factors [27]. Also, both Drosophila and mam-
malian TAF3 were found to be subunits of the respective
TFIID complexes and dimerization partners for TAF10
[28]. Interestingly, TAF3 is also a PHD containing protein
[28]. Developmental regulation of TAF3 expression has
been demonstrated [29] and it has been recently shown
that differentiation of myoblasts to myotubes involves the
replacement of a canonical TFIID complex by a
TRF3(TBP2)-TAF3 complex [30]. This previously unrecog-
nized switching of the core promoter recognition com-
plexes during differentiation may allow cells to selectively
turn on a cell type-specific transcription program.
In search for interacting partners of Dmp53, we identified
Drosophila BIP2/DmTAF3. Unlike the previously identi-
fied p53-interacting TAFs, DmTAF3 interacts with the C
terminus of Dmp53. The interaction is evolutionarily con-
served, since we show that mammalian TAF3 can bind to
both Dmp53 and human p53. Overexpression of TAF3
severely inhibits transcription activation by p53 in human
cell lines and TAF3 decreases the level of the p53 protein
as well. Thus, we identified TAF3 as an evolutionarily con-
served novel regulator of p53 transcription activation
function.
Results
Dmp53 interacts with BIP2/DmTAF3
In order to identify Dmp53-interacting partners, we
screened  Drosophila  embryonic cDNA library with the
yeast two-hybrid (Y2H) method using Dmp53 fused to
lexA DNA binding domain (DBD) as bait. Since Dmp53
contains a transcription activation domain at its N termi-
nus, to avoid false activation, we used an N-terminally
truncated version of Dmp53. Two of the identified posi-
tive clones contained partial cDNAs of the Bric-à-Brac
interacting protein gene (bip2/CG2009), that encodes for a
TBP-associated factor also called DmTAF3 [31]. A 1236 bp
long clone (clone 5) encodes amino acids 514 to 924,
while an 972 bp long clone (clone11) encodes amino
acids 738 to 1061 of DmTAF3 (Fig. 1A) indicating that
amino acids 738–924 are responsible for the interaction
with Dmp53.
To determine which region of Dmp53 is necessary for the
binding to DmTAF3, we tested various segments of
Dmp53 (Fig. 1B) for interaction with one of the identified
DmTAF3 clones (clone 5, Fig. 1A) in Y2H experiments.
The DNA binding domain of Dmp53 showed weak inter-
action, and the C terminal part of Dmp53 showed strong
interaction with DmTAF3 in the Y2H assay (Fig. 1C). In
contrast, no interaction was observed between DmTAF3
and  Drosophila  ADA2A, a transcriptional co-activator/
adaptor, indicating that the interaction between Dmp53
and DmTAF3 is specific. We tried to delineate the C-termi-
nal binding region of Dmp53, and we found that the oli-
gomerization domain alone interacted strongly, and also
the basic regulatory domain alone interacted weakly with
DmTAF3 (Fig. 1C). These data suggest that DmTAF3 inter-
acts with Dmp53 at multiple binding sites.BMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
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To test whether the interaction between DmTAF3 and
Dmp53 is direct, we performed an in vitro binding assay.
We produced the polypeptide corresponding to amino
acids 514 to 924 of DmTAF3 using rabbit reticulocyte in
vitro  transcription-translation system and bacterially
expressed and purified GST-tagged Dmp53C (Fig. 1D lane
2). The identified portion of DmTAF3 bound to GST-
Dmp53C, but not to GST (Fig. 1D lanes 3 and 4), suggest-
ing that the interaction is specific and direct.
The interaction between TAF3 and p53 is evolutionarily 
conserved
Despite the low sequence similarity between Dmp53 and
human p53, human p53 has been observed before to
interact with Drosophila  TBP [20], and other Drosophila
proteins that are also binding partners of Dmp53 [32].
Therefore, we were interested in whether DmTAF3 is able
to interact with human p53. Since human p53 also con-
tains transcription activation domain at its N-terminal
region, to avoid false positives, we used N-terminally
deleted p53 in Y2H assays (Fig. 1B). We detected strong
interaction between DmTAF3 and human p53 protein
(Fig. 1C). This result suggests that the amino acids respon-
sible for interaction with DmTAF3 are conserved in
human p53.
Next we tested whether the mammalian homolog of
DmTAF3 would interact in vitro with p53 as well. To this
end we expressed full length murine TAF3 (mTAF3) in Sf9
insect cells and produced GST, GST-Dmp53C or GST-p53
in bacteria (Fig. 1D and 2A). In these GST-pull-down
assays mTAF3 bound to GST-Dmp53C and GST-p53 (Fig.
2B lanes 3–6). Note however, that mTAF3 showed a weak
binding to GST alone under 200 mM salt washing condi-
tions (Fig. 2B lane 1), but it bound specifically to GST-
Dmp53C and GST-p53 at higher salt concentration (400
mM) (Fig. 2B lanes 4, 6) where it did not bind to the GST
control any more (Fig. 2B lane 2). These data indicate that
mTAF3 specifically interacts with p53, and also, although
less strongly, with Dmp53 suggesting that the TAF3-p53
interaction is evolutionarily conserved.
To confirm the interaction in a reverse experiment, where
we pull down TAF3, we translated full length human p53
and Drosophila ADA2A or firefly luciferase as controls in
vitro, mixed them with cell extract containing overex-
pressed mTAF3, and immunoprecipitated mTAF3-con-
taining complexes using an anti-TAF3 antibody. p53 co-
precipitated with mTAF3, while ADA2A and luciferase did
not (Fig. 2C lanes 1–3). In another control experiment,
where we added p53 and luciferase proteins together to
the cell extract containing overexpressed mTAF3, anti-
TAF3 antibody co-immunoprecipitated p53 but not luci-
ferase (Fig. 2C lane 4). Furthermore, when we added p53
to cell extract containing no mTAF3, p53 did not precipi-
Dmp53 interacts with DmTAF3 Figure 1
Dmp53 interacts with DmTAF3. (A) Full length 
DmTAF3 and the clones identified from Y2H screen as p53 
interacting proteins (clone 5 and clone 11) are depicted. 
HFD, histone fold domain; PHD, plant homeodomain. (B) 
The various portions of Dmp53 and human p53 that were 
fused to lexA-DBD and used in Y2H experiments are 
depicted. TA, transactivation domain; DBD, DNA binding 
domain; O, oligomerization domain; B, basic regulatory 
domain. (C) The indicated lexA-DBD fusion constructs were 
co-introduced into yeast with DmTAF3 amino acids 514 to 
924 fused to Gal4 activation domain (AD). Interacting pro-
teins result in complementation of His-auxotrophy and 
induction of β-galactosidase activity, which was detected by 
filter assay. Negative control was DBD-ADA2A with the 
same DmTAF3 clone. Positive control was DBD-rpb4 with 
AD-rpb7. The p53ΔN-DmTAF3 interaction was examined 
on a separate filter with the same positive and negative con-
trols, and the image was fitted into the figure. (D) Direct 
binding of DmTAF3 to Dmp53C in vitro. Coomassie stained 
gel of bacterially expressed GST (lane 1) and GST-Dmp53C 
(lane 2). DmTAF3 (aa 514–924) was expressed in vitro in the 
presence of 3H-labelled leucine and incubated with GST (neg-
ative control) or GST-Dmp53C. Glutathione-agarose bead 
bound proteins were eluted, electrophoretically separated 
and detected by autoradiography (lane3 and 4).BMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
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tate with the anti-TAF3 antibody (Fig. 2C lanes 6 and 8).
These data confirm a specific interaction between p53 and
mTAF3.
Next we investigated, whether the p53-TAF3 interaction
occurs in human cells as well. To this end, we co-trans-
fected plasmids expressing mTAF3 and p53 into 293T
cells, then we immunoprecipitated TAF3-containing com-
plexes with an anti-TAF3 antibody, and detected p53 by
Western blotting. Under these conditions, a small amount
of the overexpressed p53 co-precipitated with mTAF3 (Fig.
2D lane 3). In the control experiment, when we co-trans-
fected p53 with an empty vector, no p53 precipitated with
the anti-TAF3 antibody (Figure 2D lane 4), indicating the
specificity of the TAF3 antibody. These data together dem-
onstrate that p53 protein can interact with TAF3 in cells.
TAF3 inhibits the transcription activation function of p53
To determine the functional significance of the binding of
TAF3 to p53, we studied the effect of TAF3 overexpression
on the transactivation activity of p53. When we trans-
fected U2OS cells, which express wild type level of p53,
In vitro and in vivo binding of mTAF3 to Dmp53 and p53 Figure 2
In vitro and in vivo binding of mTAF3 to Dmp53 and p53. (A) GST and GST-p53 was expressed in bacteria as described 
in Methods, SDS-PAG was stained with Coomassie Brilliant Blue. (B) Mammalian TAF3 binds human p53 and Dmp53 as well. 
Cell extract from Sf9 cells overexpressing full length murine TAF3 was incubated with GST, GST-Dmp53C or GST-p53 bound 
to glutathione-agarose beads. Beads were washed with various concentrations of KCl as indicated above the lanes, then bound 
proteins were eluted and analysed with Western blotting using anti-TAF3 antibody. (C) TAF3 binds p53 in vitro. Drosophila 
ADA2A, human p53 and firefly luciferase were in vitro translated and transcribed using 35S-methionine. The proteins were then 
mixed with cell extract overexpressing mTAF3, an aliquot was taken for input control that was analysed by autoradiography 
(upper panel). Binding proteins were immunoprecipitated using anti-TAF3 antibody, and precipitated radioactive proteins were 
detected as above (lower panel). (D) p53 binds TAF3 in vivo. Plasmids overexpressing human p53 and mTAF3 (+) or empty vec-
tor (-) were co-transfected into 293T cells as indicated above the lanes. Complexes were immunoprecipitated using anti-TAF3 
antibody and Western blot was done using anti-p53 and anti-TAF3 antibodies.BMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
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with a luciferase reporter construct containing the p53-
responsive element from the human mdm2  gene, we
detected high luciferase activity (Fig. 3A, bar 0). When we
co-transfected increasing amounts of a plasmid overex-
pressing mTAF3, we observed a dramatic (up to 100 fold)
reduction in luciferase activity (Fig. 3A), indicating that
TAF3 severely inhibits transcription activation by p53. To
exclude that this phenomenon is cell type specific, we co-
transfected HeLa cells with the same luciferase reporter as
before together with a plasmid overexpressing p53 (since
HeLa cells contain only very limited amount of p53) and
a plasmid overexpressing mTAF3. Overexpression of TAF3
inhibited transactivation by overexpressed p53 in HeLa
cells as well (Fig 3B). Note however, that the effects
observed by using overexpressed p53 were less dramatic,
as we saw only a 45% reduction in reporter activity (Fig
3B). We wanted to further determine if the effect of TAF3
on transcription is specific to p53 or if it is a general inhi-
bition of transcription. When we co-transfected a luci-
ferase reporter driven by the cytomegalovirus (CMV)
promoter with increasing amounts of mTAF3, we found
that TAF3 had no effect on promoter activity (Figure 4A).
Thus, overexpression of TAF3 strongly and specifically
inhibits the transcriptional activity of endogenous p53.
The PHD domain of TAF3 has been found to interact with
tri-methylated histone H3 [33], thus it seems to be impor-
tant for recognizing transcriptionally active genes. There-
fore, we wanted to determine if the PHD domain of TAF3
is essential for its inhibitory role on p53. We cloned the
human TAF3 lacking the PHD domain (designated
hTAF3ΔC) from HeLa cDNA library. In co-transfection
experiments, hTAF3ΔC inhibited transactivation by p53
in HeLa cells (Fig. 4B). The degree of inhibition using
hTAF3ΔC or full length mTAF3 was comparable (40%
inhibition of transcription using 1 microgram of
hTAF3ΔC versus 30% inhibition using 1 microgram of full
length mTAF3, compare Fig. 4B and 3B). Therefore, we
conclude that the PHD domain of TAF3 is not essential for
its role as a negative regulator of p53 transcriptional activ-
ity.
Overexpression of TAF3 decreases the p53 protein level 
but has no effect on the p53 mRNA level
To further investigate the mechanism of inhibition of p53
transcriptional activity, we wanted to determine if TAF3
has an effect on the level of p53 protein. Transfection of
increasing amounts of TAF3 into U2OS cells resulted in
reduced level of endogenous p53, but no change in the
level of endogenous β-actin was observed (Figure 5A). To
exclude the cell type specificity of this phenomenon, we
co-transfected p53 and GFP with or without TAF3 into
HeLa cells. Here too, we saw down-regulation of p53, but
not GFP, protein levels upon overexpression of TAF3 (Fig-
ure 5B), indicating that TAF3 decreases the p53 protein
level. In HeLa cells the decrease in the level of p53 was
comparable to the inhibition in the transcriptional activ-
ity of p53, however, in U2OS cells the reduction in the
level of the p53 protein was not as dramatic as the reduc-
tion in the transcriptional activity of p53 (compare Fig-
ures 5 and 3) suggesting that down-regulation of p53
Overexpression of mTAF3 strongly inhibits the transcrip- tional activity of p53 Figure 3
Overexpression of mTAF3 strongly inhibits the tran-
scriptional activity of p53. (A) U2OS cells were trans-
fected with a p53-responsive luciferase reporter construct 
and the indicated amounts of plasmid overexpressing mTAF3 
(0, 0.5, 1, 2 μg) supplemented with empty vector to a total of 
3 μg DNA. (B) HeLa cells were co-transfected with 0.5 μg 
plasmid overexpressing p53 where indicated by a +, and the 
same luciferase reporter as in A, and plasmid overexpressing 
mTAF3 (0, 0.5, 1, 2 μg as indicated) supplemented with 
empty vector to a total of 3 μg DNA. Luciferase activity, 
measured 24 h post transfection, is given in arbitrary units, 
error bars indicate SD, **P < 0.01, *** P < 0.005 in t-test.BMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
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protein level may not solely be responsible for decreased
transcriptional activity of p53.
We wanted to further determine if reduced level of the p53
protein is a result of decreased level of the p53 mRNA. We
measured the level of endogenous p53 mRNA in U2OS
cells transfected with empty vector or increasing amounts
of TAF3 by performing reverse transcription and QPCR.
We found no effect of TAF3 overexpression on the level of
Inhibitory activity of TAF3 is specific for p53 and it does not  require the PHD finger motif Figure 4
Inhibitory activity of TAF3 is specific for p53 and it 
does not require the PHD finger motif. (A) TAF3 has 
no effect on CMV enhancer and promoter activity. HeLa cells 
were co-transfected with pCDNA-luciferase reporter con-
struct, plasmid overexpressing p53 (+), and the indicated 
amounts of plasmid overexpressing mTAF3 (0, 0.5, 1, 2 μg) 
supplemented to a total of 3 μg with vector DNA. Luciferase 
activity was measured 24 h post transfection and it is given 
relative to vector-transfected control. (B) Lack of the C ter-
minal PHD finger motif of TAF3 has no effect on its p53-
inhibitory activity. HeLa cells were co-transfected with a 
plasmid overexpressing p53, the p53-responsive luciferase 
reporter as in figure 3, plasmid overexpressing hTAF3ΔC (0, 
1, 3, 5 μg) and empty vector up to a total amount of 6 μg 
DNA. Luciferase activity measured 24 h post transfection is 
given in arbitrary units, error bars indicate SD, * P < 0.05 in 
t-test.
Overexpression of TAF3 decreases the level of p53 protein  but not p53 mRNA Figure 5
Overexpression of TAF3 decreases the level of p53 
protein but not p53 mRNA. (A) U2OS cells were 
untransfected (U) or co-transfected with various amounts of 
plasmid expressing mTAF3 (0, 1, 2, 4 μg as indicated above 
the panel), and empty vector to a total of 4 μg DNA. p53 
protein level in the cells was examined by Western blotting 
and the same blot was immunoblotted with anti-actin anti-
body for internal control. (B) HeLa cells were co-transfected 
with p53 expression construct, GFP-expression construct 
for control, and empty vector (0) or 4 μg of plasmid express-
ing mTAF3 (4). Cell lysates were prepared 24 h after trans-
fection and analysed by Western blotting using anti-TAF3, 
anti-p53, or anti-GFP antibodies as indicated. (C) U2OS cells 
were co-transfected with various amounts of plasmid 
expressing mTAF3 (0, 1, 2, 4 μg) and empty vector to a total 
of 4 μg DNA. p53 and for internal control, GAPDH mRNA 
level was examined by QPCR, p53 mRNA level was normal-
ized to GAPDH mRNA level in each sample, and expressed 
relative to normalized p53 mRNA level in vector-transfected 
control.BMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
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p53 mRNA (Figure 5C) suggesting that TAF3 does not
influence the mRNA expression of p53, but rather affects
the protein expression or turnover of p53. Thus, we con-
clude that TAF3 may inhibit transcription activation func-
tion of p53 partly by reducing the level of p53 protein.
Discussion
BIP2/DmTAF3 was first identified in a yeast two hybrid
screen as an interacting partner of BAB1 and BAB2 (Bric à
brac 1 and 2) developmentally regulated transcription fac-
tors, which are involved in pattern formation and mor-
phogenesis in Drosophila [27]. The BTB/POZ domains of
BAB1 and BAB2 were shown to mediate the direct interac-
tion with BIP2/TAF3, and amino acids 859 to 1091 in the
middle part of BIP2/DmTAF3 were responsible for the
binding to BAB1/2. Whether the interaction between
BAB1/2 and BIP2/DmTAF3 mediates transcriptional acti-
vation or repression has not been determined.
BIP2/DmTAF3 was also identified as TAFII155, the Dro-
sophila homolog of yeast TAF3, formerly called yTAFII47
[28]. DmTAF3 was shown to heterodimerize with
DmTAF10 and to be a component of the general transcrip-
tion factor TFIID. DmTAF3 localizes to puffs and inter-
bands on polytene chromosomes, which correspond to
transcriptionally active chromatin. The mammalian
homolog of DmTAF3 was designated TAFII140 [28] and
later called TAF3 [31]. Human TAF3 was also shown to
bind to TAF10 through its histone fold domain and to be
a component of both TFIID and TFTC. TAF10 relies on
TAF3, among other TAFs, for its nuclear import [34].
TAF3 expression is developmentally regulated, as it is
strongly expressed in early spermatocytes, but it is down-
regulated in haploid cells [29]. Differentiation of myob-
lasts to myotubes involves the disruption of a "normal"
TFIID complex and its replacement by a not yet well char-
acterized TRF3(TBP2)-TAF3 complex [30]. The switching
of core promoter recognition complexes during differenti-
ation provides cells to selectively turn on one transcrip-
tion program, while silencing many others, and thus it
may represent a general mechanism for regulating cell
type-specific terminal differentiation.
Here we identified TAF3 (Drosophila and mammalian) as
an interacting partner of p53. The central region, amino
acids 738 to 924 of DmTAF3 mediates the interaction
with p53 (Fig. 1A), a region distinct from the proposed A/
T hook domain (amino acids 574–586). Interestingly,
several researchers have recently identified the same cen-
tral region of DmTAF3 to interact with various transcrip-
tion factors, such as GAGA factor (amino acids 612–
1073) [35], Antennapedia (amino acids 853–1088) [36]
and BAB1/2 (amino acids 859 to 1091) [27]. Although
this central region of DmTAF3 shows low degree of simi-
larity to the corresponding core region of mammalian
TAF3 (amino acids 497 to 608 of murine TAF3) [28], we
propose that it may serve as a transcription factor-binding
domain responsible for interaction with other, yet uni-
dentified transcription factors as well. We think that the
TAF3-p53 interaction is direct and does not involve previ-
ously characterized p53 interacting components of TFIID,
since we detected in vitro binding between bacterially
expressed Dmp53 and in vitro translated portion of
DmTAF3 (Fig. 1D). The interaction is evolutionarily con-
served, since DmTAF3 can also interact with human p53
(Fig. 1C), as well as mammalian TAF3 can bind to both
Dmp53 and human p53 in heterologous systems (Fig. 2).
Importantly, unlike previously identified TAFs that inter-
act with the N terminal transcription activation domain of
p53 and mediate transcription activation, TAF3 interacts
with the C terminal oligomerization and regulatory
domain of p53 and represses p53 activity.
Elevated TAF3 expression strongly inhibits transcription
activation by p53 in at least two human cell lines contain-
ing either endogenous or overexpressed p53 (Fig. 3). This
effect of TAF3 is specific to p53, since we found no effect
of TAF3 on transcription regulated by the CMV promoter
(Fig. 4A) indicating that it does not inhibit the transcrip-
tional activity of the factors that bind to these elements.
Furthermore, in other studies TAF3 had no inhibitory
effect on ATF7 [37], and it even acted as a coactivator for
WDR5-dependent genes [33]. The PHD finger is a special-
ized form of zinc finger that is classically characterized by
C4HC3 arrangement of cysteine and histidine residues
involved in Zn coordination [38]. The PHD finger was
shown to be essential for the coactivator activity of TAF3
[33], in contrast, we found that the PHD finger was not
required for the inhibitory activity of TAF3 on p53.
Although most PHD finger containing proteins were
implicated in mediating interaction with chromatin
[33,39,40], other reports described E3 ubiquitin ligase
activity of PHD containing viral and cellular proteins [41-
44]. Since we found that overexpression of TAF3 reduces
p53 protein level (Fig. 5), we examined the possibility that
TAF3 may act as an E3 ubiquitin ligase for p53. However,
in our preliminary experiments we could not detect any
ubiquitin ligase activity of TAF3 towards p53 in either in
vitro or in vivo ubuiquitination assays (data not shown).
Because TAF3 is a subunit of TFIID, and interacts with sev-
eral additional proteins [45], it is conceivable that TAF3
recruits a ubiquitin ligase to p53 to increase its turnover.
In HeLa cells the reduction in the level of p53 was compa-
rable to the reduction seen in the transcriptional activity
of p53, while in U2OS cells the decrease in the level of the
p53 protein was not as dramatic as the reduction seen in
the transcriptional activity of p53 (Figures 3 and 5). This
latter observation suggests that down-regulation of p53
protein level by TAF3 may not solely be responsible forBMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
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reduced transcriptional activity of p53, but additionally,
TAF3 may directly inhibit the transcriptional activity of
p53. We speculate that the additional mechanisms TAF3
employs to inhibit p53 transcriptional activity may
include posttranslational modifications, such as sumoyla-
tion [46], but the exact mechanisms remain to be eluci-
dated.
Conclusion
Here we identify TAF3 as an evolutionarily conserved neg-
ative regulator of p53 transcription activation function.
We show physical interaction between the C terminus of
Dmp53 and the central region of TAF3 both in yeast two
hybrid assays and in vitro. The interaction is evolutionarily
conserved, since DmTAF3 can also interact with human
p53, and mammalian TAF3 can bind to both Dmp53 and
human p53. Elevated TAF3 expression results in severe
specific inhibition of transcription activation by p53 in
human cell lines, which may be partly due to a decrease in
the level of the p53 protein.
Methods
Plasmid constructs
Bait plasmids pBTM116-Dmp53ΔN (amino acids 47–
385), pBTM116-Dmp53ΔNΔC (amino acids 47–294)
pBTM116-Dmp53C (amino acids 277–385), pBTM116-
Dmp53C1 (amino acids 277–351), pBTM116-Dmp53C2
(amino acids 349–385), pBTM116-p53ΔN, pGEX4T1-
Dmp53C and pXJ41-mTAF3 were described previously
[28,32]. The cDNA encoding DmTAF3 amino acids 514 to
924 was cloned in frame into pET28c (Novagen). Human
full length p53 was cloned in frame into pGEX6P1 vector
(Amersham Biosciences) using BamHI and XhoI restric-
tion sites. To generate pCDNAflag-hTAF3ΔC cDNA from
HeLa cells was PCR-amplified using the following prim-
ers: hTAFfw AGAATTCAGTTACTCCAGGTCGTTGTTG,
hTAFrev AAAGTCGACGGAAGCACTGGCAACAAAG. The
resulting PCR product was cloned into pCDNAflag using
EcoRI and SalI restriction sites. To construct the baculovi-
rus expression vector for TAF3, the full length mTAF3
cDNA was excised from the pXJ41-Flag-TAF3 expression
vector by EcoRI and Bam HI and inserted in the corre-
sponding sites of the pVL1392 baculovirus expression vec-
tor. The generation of the Flag-TAF3 expressing
recombinant baculovirus and the Sf9 cell infection was
done under standard conditions [47].
Yeast two-hybrid experiments
The yeast two-hybrid screen was performed following the
manufacturer's recommendations using MATCHMAKER
LexA Two-Hybrid System with the MATCHMAKER Dro-
sophila  embryonic cDNA library cloned into pACT2
(Clontech Laboratories, Inc.) as previously described [32].
Positive clones were validated by β-galactosidase colony-
lift filter assay [48]. Plasmid DNA was isolated from colo-
nies proved to be positive in both complementation of
auxotrophy and β-galactosidase assays, sequenced and
cDNAs identified by BLAST homology searches [49].
In vitro binding assays
DmTAF3(514–924) was transcribed and translated from
pET28c-DmTAF3clone5 in the presence of 3H leucine
using the TNT T7 Qiuck-coupled transcription-translation
system (Promega) following the manufacturer's instruc-
tions. pGEX4T1-Dmp53C, pGEX6P1 or pGEX6P1-p53
was introduced into E. coli strain BL21, protein expression
was induced by treatment with IPTG over night at 37°C.
Expressed GST-Dmp53C or GST was bound to glutath-
ione sepharose high performance beads (Amersham Bio-
sciences) according to the manufacturer's instructions,
incubated with labelled DmTAF3(514–924) and interac-
tion was analysed as described before [32].
Sf9 cell extract overexpressing murine TAF3 by baculoviral
expression system [34] was incubated with bacterially
expressed GST, GST-Dmp53C or GST-p53 bound to glu-
tathione sepharose beads over night at 4°C as previously
described. Beads were washed with various concentra-
tions of KCl as indicated in Figure 2B, then bound pro-
teins were analysed with SDS-PAGE and Western blotting
using anti-TAF3 antibody 39TA1C7 [28].
Full length human p53, Drosophila melanogaster ADA2A
and firefly luciferase as control were transcribed and trans-
lated in the presence of 35S methionine using the TNT T7
Quick-coupled transcription-translation system
(Promega) following the manufacturer's instructions. Sf9
cell extract overexpressing murine TAF3 was incubated
with the indicated (Fig. 2C) single labelled protein or p53
and luciferase together, and complexes were immunopre-
cipitated using anti-TAF3 antibody 39TA2F5 as described
before [34]. Precipitated complexes were washed 3 times
with PBS and once with PBS supplemented with 200 mM
KCl. Labelled proteins were detected by SDS-PAGE and
fluorography (using Amplify Fluorographic Reagent from
Amersham Biosciences).
Cell culture, transfection and luciferase reporter assays
HeLa human cervical carcinoma, U2OS human osteosar-
coma and 293T human embryonal kidney cells were
maintained in Dulbecco's modified Eagle's medium, sup-
plemented with 5% (for HeLa) or 10% (for U2OS and
293T) foetal bovine serum in 5% CO2 incubators at
37°C. For Western blotting and QPCR U2OS cells were
transfected on 60 mm dishes using ExGen transfection
reagent (Fermentas) with the amount of pXJ41-mTAF3
indicated on the figures, supplemented to a total of 4 μg
with empty vector DNA. For Western blotting HeLa cells
were transfected with 0.5 μg pCDNA3p53Pro, 0.5 μg
pEGFP and the indicated amount of pXJ41-mTAF3 sup-BMC Molecular Biology 2008, 9:57 http://www.biomedcentral.com/1471-2199/9/57
Page 9 of 11
(page number not for citation purposes)
plemented to 5 μg with empty vector. For luciferase
reporter assays cells were transfected in 6-well plates with
0.5  μg pGL2NaLuc reporter (p53-responsive construct
from the mdm2 gene) or pCDNA3-luc reporter and 0.5 μg
pCDNA3p53Pro where indicated and with the amount of
pXJ41-mTAF3 or pCDNA3flag-hTAF3ΔC indicated on the
figures, supplemented to a total of 3 or 6 μg with empty
vector DNA, respectively. Twenty-four hours after trans-
fection cells were lysed with Reporter Lysis Buffer
(Promega), and luciferase reporter assay was performed
using Luciferase Assay System as recommended by the
manufacturer (Promega). As a control for equal cell
number after transfection, protein concentration of the
samples was measured using Bradford reagent (Bio-Rad).
Mean and standard deviation of luciferase activity data
was calculated from three separate experiments, and P-
values were calculated using paired t-test.
Immunoprecipitation and Western blotting
For co-immunoprecipitation assay 293T cells were trans-
fected on 14 cm dish using JetPEI (Q-Bio Gene) with 7 μg
pCDNA3p53Pro and 7 μg pXJ41-mTAF3 or empty vector
DNA. Cells were lysed 48 h after transfection and immu-
noprecipitation of TAF3-complexes was performed as
described before using anti-TAF3 39TA1C7 antibody [28].
Western blotting and immunodetection was performed
using anti-human p53 DO-1 (Santa Cruz Biotechnology)
or DO-7 (Dako Cytomation), anti-actin20-33 (Sigma),
anti-GFP (Invitrogen), anti-TAF3 39TA1C7 [28] primary
antibodies, and anti-mouse-HRP (Dako Cytomation) or
anti-kappa light chain-HRP (for detection of p53 after co-
IP) secondary antibodies.
Quantitative RT-PCR
Total RNA was isolated with Qiagen RNeasy mini kit
(Qiagen Inc.) according to the manufacturer's instruc-
tions. First-strand cDNA was synthesized from 2 μg total
RNA with random hexamer primers using TaqMan
Reverse Transcription Reagent (Applied Biosystems). PCR
reactions were carried out in duplicates in an ABI Prism
7500 real-time PCR system using SYBR-Green PCR Master
Mix and the following primers: hp53For CCCTTCCCA-
GAAAACCTACC, hp53Rev CTCCGTCATGTGCTGTGACT,
GAPDHfor ACCTGACCTGCCGTCTAGAA, GAPDHrev
TCCACCACCCTGTTGCTGTA. The Ct value for each stud-
ied mRNA was normalized to the GAPDH internal control
and the change of expression levels of the examined genes
were calculated by the ΔΔCt method.
Abbreviations
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